Apixaban or Vitamin K Antagonists for Stroke Prevention in Patients With Atrial Fibrillation on Hemodialysis: Results of the Randomized Axadia-AFNET 8 Trial

被引：0
|
作者：
Reinecke, Holger [1 ]
Bauersachs, Rupert [2 ]
Breithardt, Gunter [3 ]
Engelbertz, Christiane [3 ]
Gerss, Joachim [4 ]
Gaerlich, Dennis [4 ]
Juergensmeyer, Sabine [5 ]
Wanner, Christoph [6 ]
Kirchhof, Paulus [7 ]
机构：
[1] Univ Hosp Muenster, Dept Cardiol, Munster, Germany
[2] Agaples Bethanien Hosp, Med Care Cntr, Frankfurt, Germany
[3] Univ Hosp Muenster, Dept Cardiol, Munster, Germany
[4] Univ Munster, Inst Biostat & Clin Rsch, Munster, Germany
[5] Atrial Fibrillat Network, Munster, Germany
[6] Univ Hosp, Div Nephrol, Dept Med, Wurzburg, Germany
[7] Univ Hosp Hamburg Eppendorf, Dept Cardiol, Hamburg, Germany
来源：
CIRCULATION | 2022年 / 146卷 / 25期
关键词：
atrialfibrillation; apixaban; vitamin K antagonist; hemodialysis; randomized; controlled trial; stroke prevention;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
18519
引用
收藏
页码：E589 / E590
页数：2
相关论文
共 50 条
  • [41] Cost-effectiveness of Apixaban versus Warfarin and Aspirin in Sweden for Stroke Prevention in Patients with Atrial Fibrillation
    Lanitis, Tereza
    Kongnakorn, Thitima
    Jacobson, Lena
    De Geer, Anna
    THROMBOSIS RESEARCH, 2014, 134 (02) : 278 - 287
  • [42] Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective
    Kostas Athanasakis
    Nadia Boubouchairopoulou
    Eleftheria Karampli
    Filippos Tarantilis
    Paraskevi Savvari
    Aikaterini Bilitou
    John Kyriopoulos
    American Journal of Cardiovascular Drugs, 2017, 17 : 123 - 133
  • [43] Temporal trends in the prescription of vitamin K antagonists in patients with atrial fibrillation
    Friberg, J
    Gislason, GH
    Gadsboll, N
    Rasmussen, JN
    Rasmussen, S
    Abildstrom, SZ
    Kober, L
    Madsen, M
    Torp-Pedersen, C
    JOURNAL OF INTERNAL MEDICINE, 2006, 259 (02) : 173 - 178
  • [44] Anticoagulation control in different ethnic groups receiving vitamin K antagonist therapy for stroke prevention in atrial fibrillation
    Zulkifly, Hanis
    Cheli, Paola
    Lutchman, Ivana
    Bai, Ying
    Lip, Gregory Y. H.
    Lane, Deirdre A.
    THROMBOSIS RESEARCH, 2020, 192 : 12 - 20
  • [45] Switching to Direct Anticoagulation or Continued Vitamin-K Antagonists in Frail Patients With Atrial Fibrillation in Whom Vitamin-K Antagonists Are Tolerated?
    Wallentin, Lars
    Giugliano, Robert P.
    CIRCULATION, 2024, 149 (04) : 290 - 292
  • [46] Improving stroke prevention therapy for patients with atrial fibrillation in primary care: protocol for a pragmatic, cluster randomized trial
    Lee, Theresa M.
    Ivers, Noah M.
    Bhatia, Sacha
    Butt, Debra A.
    Dorian, Paul
    Jaakkimainen, Liisa
    Leblanc, Kori
    Legge, Dan
    Morra, Dante
    Valentinis, Alissia
    Wing, Laura
    Young, Jacqueline
    Tu, Karen
    IMPLEMENTATION SCIENCE, 2016, 11
  • [47] Protocol for AREST: Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation - A Randomized Controlled Trial of Early Anticoagulation After Acute Ischemic Stroke in Atrial Fibrillation
    Rose, David Z.
    Meriwether, John N.
    Fradley, Michael G.
    Renati, Swetha
    Martin, Ryan C.
    Kasprowicz, Thomas
    Patel, Aarti
    Mokin, Maxim
    Murtagh, Ryan
    Kip, Kevin
    Bozeman, Andrea C.
    McTigue, Tara
    Hilker, Nicholas
    Kirby, Bonnie
    Wick, Natasha
    Nhi Tran
    Burgin, W. Scott
    Labovitz, Arthur J.
    FRONTIERS IN NEUROLOGY, 2019, 10
  • [48] Non-Vitamin K Oral Anticoagulants for Stroke Prevention in Special Populations with Atrial Fibrillation
    Arnaud Bisson
    Denis Angoulvant
    Raphael Philippart
    Nicolas Clementy
    Dominique Babuty
    Laurent Fauchier
    Advances in Therapy, 2017, 34 : 1283 - 1290
  • [49] Transient ischemic attacks in patients with atrial fibrillation - Implications for secondary prevention: The European Atrial Fibrillation Trial and Stroke Prevention in Atrial Fibrillation III Trial
    Hart, RG
    Pearce, LA
    Koudstaal, PJ
    STROKE, 2004, 35 (04) : 948 - 951
  • [50] Cost-effectiveness analysis of apixaban compared to other direct oral anticoagulants for prevention of stroke in Austrian atrial fibrillation patients
    Walter, Evelyn
    Voit, Marco
    Eichhober, Gerald
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (02) : 265 - 275
12345